Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study

Tanguy Dequidt; Quentin Richier; Céline Louapre; Florence Ader; Yanis Merad; Nicolas Lauwerier; Christine Jacomet; Michel Carles; Charlotte Biron; Vincent Gendrin; Clément Marlat; François Danion; Tristan M Lepage; Albert Sotto; Loïc Bourdellon; Alexandre Mania; Martin Martinot; Georges Le Falher; Alexis Ferre; Benoit Pilmis; Guillaume Gondran; Pierre Simeone; Matthieu Henry; Toufik Kamel; Simon Ray; Sophie Ancellin; Nicolas Mélé; Fabrice Camou; Marjolaine Destremau; Jeremy Sellenet; Noémie Zucman; Marion Le Maréchal; Khawla Mellouki; Marie-Elodie Langlois; David Luque Paz; Maud Mousset; Catherine Leclerc; Agnès Sommet; Karine Lacombe; Guillaume Martin-Blondel

doi:10.1016/j.ijid.2024.107323

Retour

Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study

Article de revue

Avec comité de lecture

Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study

Tanguy Dequidt, Quentin Richier, Céline Louapre, Florence Ader, Yanis Merad, Nicolas Lauwerier, Christine Jacomet, Michel Carles, Charlotte Biron, Vincent Gendrin, …

International journal of infectious diseases, Vol.151, p.107323

01/02/2025

DOI: https://doi.org/10.1016/j.ijid.2024.107323

PMID: 39643155

Résumé

Anti-CD20 antibodies

Convalescent plasma

Multiple sclerosis

Neuromyelitis optica

Protracted COVID-19

SARS-CoV-2

•Overall 30-day survival after CCP was 97% [IC95%: 91-99]).•Protracted COVID-19 persisted for 51 [28-69] days (184 days maximum) before CCP.•Fever resolved in all patients with protracted COVID-19 seven days after CCP.•Clinical improvement was 98% at day 30 after CCP in protracted COVID-19.•High-titre CCP may be useful for late protracted COVID-19 in seronegative patients. Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 convalescent plasma (CCP) in patients with MS or NMOSD exposed to anti-CD20 and infected by SARS-CoV-2. This French national, retrospective cohort study was conducted between November 2020 and June 2023. Patients with MS or NMOSD, under anti-CD20 mAbs, with symptomatic COVID-19 and treated by CCP were screened. Protracted COVID-19 was defined by a duration of symptoms >21 days. The primary endpoint was the overall survival 30 days after CCP administration. Ninety-two patients from 34 hospitals were included, 84 (91%) with MS and 8 (9%) with NMOSD. Overall, 30-day survival was 97% (IC95%: 91-99). SARS-CoV-2 viremia was positive in 47/75 (61%) patients before CCP versus 9/59 (15%) seven days post-CCP. In the 52 patients (57%) with protracted COVID-19, the duration of symptoms before CCP was 51 [28-69] days, including fever in 75% of cases, which disappeared in 100% of patients 7 days post-CCP. CCP could be a therapeutic option in patients exposed to anti-CD20 mAbs for inflammatory demyelinating disease, particularly in those with protracted COVID-19.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study
Créateurs - sans rôle: Tanguy Dequidt - Department of Infectious Diseases, Guadeloupe University hospital, Pointe-à-Pitre, France
Quentin Richier - Sorbonne University, Department of Infectious Diseases, Saint Antoine Hospital, APHP, Paris, France
Céline Louapre - Sorbonne University, Department of Neurology, Pitié Salpêtrière Hospital, APHP, CIC neurosciences, Paris Brain Institute, Paris, France
Florence Ader - Hospices Civils de Lyon
Yanis Merad - Department of Infectious Diseases, Hospices Civils de Lyon, Lyon, France
Nicolas Lauwerier - Department of Infectious Diseases, Lille University Hospital, Lille, France
Christine Jacomet - Department of Infectious Diseases, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
Michel Carles - Department of Infectious Diseases, Nice University Hospital, Nice, France
Charlotte Biron - Department of Infectious Diseases, Nantes University Hospital, Nantes, France
Vincent Gendrin - Department of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France
Clément Marlat - Department of Infectious Diseases, Rouen University Hospital, Rouen, France
François Danion - Department of Infectious Diseases, Strasbourg University Hospital, Strasbourg, France
Tristan M Lepage - Department of Infectious Diseases, Montpellier University Hospital, Montpellier, France
Albert Sotto - Department of Infectious Diseases, Nimes University Hospital, Nimes, France
Loïc Bourdellon - Medicine A unit, Emile Durkheim Hospital, Epinal, France
Alexandre Mania - Department of Internal Medicine, Henri Mondor Hospital, Aurillac, France
Martin Martinot - Department of Infectious Diseases, Colmar Hospital, Colmar, France
Georges Le Falher - Department of Internal Medicine, Béziers Hospital, Béziers, France
Alexis Ferre - Intensive Care Unit, Versailles Hospital, Le Chesnay, France
Benoit Pilmis - Antimicrobial Stewardship Team, Microbiology Unit, Groupe Hospitalier Paris Saint Joseph, Paris, France
Guillaume Gondran - Department of Internal Medicine, Limoges University Hospital, Limoges, France
Pierre Simeone - Department of Anesthesiology and Critical Care Medicine, University Hospital Timone, APHM, Marseille, France
Matthieu Henry - Medical-Surgical Intensive Care Unit, District Hospital Center, La Roche sur Yon, France
Toufik Kamel - Intensive Care Unit, Orléans University Hospital, Orléans, France
Simon Ray - Department of Infectious Diseases, Rodez Hospital, Rodez, France
Sophie Ancellin - Department of Infectious Diseases, Auch Hospital, Auch, France
Nicolas Mélé - Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Sainte-Anne Hospital, Paris, France
Fabrice Camou - Intensive Care and Infectious Disease Unit, Groupe Saint-André, Bordeaux University Hospital, Bordeaux, France
Marjolaine Destremau - Intensive Care and Infectious Disease Unit, Groupe Saint-André, Bordeaux University Hospital, Bordeaux, France
Jeremy Sellenet - Department of Internal Medicine, Saint Jean Sud de France Clinic, Saint-Jean-de-Vedas, France
Noémie Zucman - Intensive Care Unit, CH Annecy Genevois, Epagny Metz-Tessy, France
Marion Le Maréchal - Univ. Grenoble Alpes, Infectious Diseases Department, CHU Grenoble Alpes, Grenoble, France
Khawla Mellouki - Department of Infectious Diseases, Claude Bernard University Lyon 1, Valence Hospital Center, Valence, France
Marie-Elodie Langlois - Department of Internal Medicine and Infectious Diseases, Saint Joseph Saint Luc Hospital, Lyon, France
David Luque Paz - Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France
Maud Mousset - Intensive Care Unit, Comminges Pyrénées Hospital, Saint-Gaudens, France
Catherine Leclerc - Department of Infectious Diseases, CHI Poissy - Saint-Germain-en-Laye, Saint-Germain-en-Laye, France
Agnès Sommet - Clinical Investigation Center, Toulouse University Hospital, Toulouse, France
Karine Lacombe - Sorbonne University, IPLESP Inserm, Infectious Diseases Department, Saint Antoine Hospital, APHP, Paris, France
Guillaume Martin-Blondel - Department of Infectious Diseases, Toulouse University Hospital, Toulouse, France
Détails de publication: International journal of infectious diseases, Vol.151, p.107323
Éditeur: Elsevier Ltd
Identifiants: 99158629509311
Unité académique: Virulence Bacterienne et Infections Chroniques - VBIC; Recherches translationnelles sur le VIH et les Maladies Infect. Endém. émerg. - TransVIHMI
Langue: English
Type de ressource: Journal article